Dalbavancin

Description: Dalbavancin (BI-397), a novel second-generation lipoglycopeptide antibiotic, possesses in vitro activity against a variety of Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE),Dalbavancin inhibits Staphylococcus aureus and Bacillus anthracis with MIC90s of 0.06 µg/mL and 0.25 µg/mL, respectively. Target: Antibacterial, Antibiotic. Smiles: [H][C@@]1(Oc2c3Oc4ccc(C[C@@]5([H])NC(=O)[C@H](NC)c6ccc(O)c(Oc7cc(O)c(Cl)c(c7)[C@]([H])(NC5=O)C(=O)N[C@]5([H])c(c3)cc2Oc2ccc(cc2Cl)[C@@H](O)[C@]2([H])NC(=O)[C@]([H])(NC5=O)c3ccc(O)c(c3)-c3c(O[C@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]5O)cc(O)cc3[C@H](NC2=O)C(=O)NCCCN(C)C)c6)cc4)O[C@@H]([C@@H](O)[C@H](O)[C@H]1NC(=O)CCCCCCCCC(C)C)C(O)=O. References: Scoble PJ, Owens RC Jr, Puttagunta S, Yen M, Dunne MW. Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects. Clin Drug Investig. 2015 Oct 12. [Epub ahead of print] PubMed PMID: 26458939.